Last reviewed · How we verify
Fluarix™ VB
Fluarix VB is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Fluarix VB is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Fluarix™ VB |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens from multiple seasonal strains, which trigger both humoral and cellular immune responses. This primes the immune system to recognize and neutralize circulating influenza viruses, reducing infection risk and severity. The 'VB' designation likely indicates a specific formulation or manufacturing process variant.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness
- Injection site erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |